Skip to main content

Fundraising for Biotech in 2023: Where's the Money?


Date: April 11, 2023

Time: 4:00PM - 6:00PM (EST)

Location: Mintz San Diego Office

Increasingly, biotech companies and SMEs, in particular, are faced with fundraising challenges and the prospect of embarking on equity down-rounds. For those experienced in riding the ups and downs of the market, this is when alternative fundraising strategies are embraced. As a biotech executive, are you well versed in your financing options?

Join us for a fireside chat to hear legal and industry professionals discuss:

  • The state of the market in 2023 and what’s on the horizon
  • Viewpoints from venture capital
  • How non-dilutive bridge financing can lead to an equity round
  • Utilizing JVs, partnerships, and R&D collaborations to share costs and generate revenue
  • Grant-funding options
  • The role of IP valuations in unlocking value


Jeremy Glaser Headshot

Jeremy D. Glaser


Jeremy D. Glaser is Co-chair of Mintz's Venture Capital & Emerging Companies Practice. He has over three decades of experience guiding life sciences and technology companies in growth and financing strategies, including public offerings, financings, mergers and acquisitions, and SEC compliance.

David H. Crean


Managing General Partner, Cardiff Advisory LLC

Gary T. Choy, MBA


Co-Founder & Chief Executive Officer, f5 Therapeutics Incorporated

Pascal Krotee, PhD


Senior Associate, RiverVest